Taizhou-based MabPharm Ltd (HKG: 2181), a specialist in monoclonal antibody (mAb) biosimilars, has announced the receipt of market approval for CMAB807, a biosimilar version of Johnson & Johnson’s (J&J, NYSE: JNJ) Remicade (infliximab), in Indonesia, with a similar approval in Peru in July this year. The approval encompasses all six indications, including adult ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, adult and childhood Crohn’s disease, fistula Crohn’s disease, and psoriasis.
CMAB807: A Biosimilar with Broad Indication Coverage
CMAB807, the first infliximab copycat approved in China and the first Chinese infliximab knockoff in Indonesia, has been licensed to Kexing Pharma (SHA: 688136) for exclusive global promotion, excluding mainland China, Japan, Europe, and North America. This licensing deal, which took place in June 2021, was expanded in March 2022 to include mainland China, further broadening the reach of CMAB807.
Expanding Global Access to Biosimilar Infliximab
The approvals and licensing agreements for CMAB807 mark a significant step forward in making biosimilar versions of infliximab more accessible to patients globally. By offering a biosimilar option, MabPharm Ltd contributes to the expansion of treatment options for a range of autoimmune and inflammatory conditions, potentially improving patient outcomes and reducing the financial burden of healthcare systems.-Fineline Info & Tech
